[go: up one dir, main page]

CN112867733A - 抗cd137抗体及其应用 - Google Patents

抗cd137抗体及其应用 Download PDF

Info

Publication number
CN112867733A
CN112867733A CN201880098756.0A CN201880098756A CN112867733A CN 112867733 A CN112867733 A CN 112867733A CN 201880098756 A CN201880098756 A CN 201880098756A CN 112867733 A CN112867733 A CN 112867733A
Authority
CN
China
Prior art keywords
amino acid
antibody
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880098756.0A
Other languages
English (en)
Other versions
CN112867733B (zh
Inventor
徐霆
彭建建
付凯
马慧
潘晓龙
傅士龙
马树立
丁健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shihuida Pharmaceuticals Group (JILIN) Ltd
Original Assignee
Dingfu Biotarget Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dingfu Biotarget Co ltd filed Critical Dingfu Biotarget Co ltd
Publication of CN112867733A publication Critical patent/CN112867733A/zh
Application granted granted Critical
Publication of CN112867733B publication Critical patent/CN112867733B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

提供了一种可以特异性结合CD137的抗体或其抗原结合片段，其轻链可变区和重链可变区包括一个或多个突变。还提供了所述抗体或其抗原结合片段在制备药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (41)

  1. PCT国内申请，权利要求书已公开。
CN201880098756.0A 2018-10-19 2018-10-19 抗cd137抗体及其应用 Active CN112867733B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/111086 WO2020077635A1 (zh) 2018-10-19 2018-10-19 抗cd137抗体及其应用

Publications (2)

Publication Number Publication Date
CN112867733A true CN112867733A (zh) 2021-05-28
CN112867733B CN112867733B (zh) 2023-01-06

Family

ID=70283644

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880098756.0A Active CN112867733B (zh) 2018-10-19 2018-10-19 抗cd137抗体及其应用
CN201980068277.9A Active CN112867737B (zh) 2018-10-19 2019-09-12 抗cd137抗体及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980068277.9A Active CN112867737B (zh) 2018-10-19 2019-09-12 抗cd137抗体及其应用

Country Status (5)

Country Link
US (1) US12252542B2 (zh)
EP (1) EP3885364A4 (zh)
JP (1) JP7466930B2 (zh)
CN (2) CN112867733B (zh)
WO (2) WO2020077635A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105855A1 (en) * 2002-07-30 2004-06-03 Kunkel Maria Jure Humanized antibodies against human 4-1BB
EP1670828A1 (en) * 2003-10-10 2006-06-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
CN1867585A (zh) * 2003-10-10 2006-11-22 布里斯托尔-迈尔斯·斯奎布公司 抗人4－1bb(cd137)的完全人抗体
CN108026169A (zh) * 2015-09-22 2018-05-11 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
CN1289668C (zh) * 2003-06-12 2006-12-13 北京安波特基因工程技术有限公司 一种用于抗体改形的体外分子定向进化方法
EP2399935A3 (en) * 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
CN114380908B (zh) * 2015-10-15 2023-03-17 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
JP7138630B2 (ja) * 2016-07-14 2022-09-16 ゲンマブ エー／エス Ｃｄ４０およびｃｄ１３７に対する多重特異性抗体
JP7274417B2 (ja) * 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
CA3039772C (en) 2017-01-06 2020-08-25 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105855A1 (en) * 2002-07-30 2004-06-03 Kunkel Maria Jure Humanized antibodies against human 4-1BB
EP1670828A1 (en) * 2003-10-10 2006-06-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
CN1867585A (zh) * 2003-10-10 2006-11-22 布里斯托尔-迈尔斯·斯奎布公司 抗人4－1bb(cd137)的完全人抗体
US20090068192A1 (en) * 2003-10-10 2009-03-12 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN108026169A (zh) * 2015-09-22 2018-05-11 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用

Also Published As

Publication number Publication date
EP3885364A4 (en) 2022-09-07
WO2020078149A1 (zh) 2020-04-23
CN112867737B (zh) 2023-01-06
JP2022512724A (ja) 2022-02-07
US20210380708A1 (en) 2021-12-09
WO2020077635A1 (zh) 2020-04-23
CN112867733B (zh) 2023-01-06
US12252542B2 (en) 2025-03-18
CN112867737A (zh) 2021-05-28
EP3885364A1 (en) 2021-09-29
JP7466930B2 (ja) 2024-04-15

Similar Documents

Publication Publication Date Title
JP7589314B2 (ja) 抗ｐｄ－１／抗ｖｅｇｆａ二官能性抗体、その医薬組成物およびその使用
KR102503084B1 (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
JP7082620B2 (ja) 抗ｐｄ１モノクローナル抗体、その医薬組成物およびその使用
JP2023541473A (ja) 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用
JP7466930B2 (ja) 抗ｃｄ１３７抗体およびその使用
CN116199777B (zh) 抗hNKG2D抗体及其应用
EA042365B1 (ru) Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение
EA042479B1 (ru) Моноклональное антитело против pd1, его фармацевтическая композиция и их применение
NZ791621A (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240910

Address after: No. 999, High tech Industrial Park, Baishan City, Jilin Province, China

Patentee after: SHIHUIDA PHARMACEUTICALS GROUP (JILIN) Ltd.

Country or region after: China

Address before: 2nd and 3rd floors, auxiliary building, Wanlong Building, No. 29 Xinfa Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, China 215127

Patentee before: DINGFU BIOTARGET Co.,Ltd.

Country or region before: China